Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

A Proof-of-concept Study With NVDX3, an Osteogenic Implant of Human Allogenic Origin, in the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Spine Fusion in Adults.

Prospective, single arm, single-center clinical study to test NVDX3 in patients suffering from low grade one level degenerative lumbar (L1 - S1) spondylolisthesis. NVDX3 will be implanted during a single surgical intervention.

Study Overview

• Status: Active, not recruiting
• Conditions: Degenerative Lumbar Spondylolisthesis
• Intervention / Treatment: Drug: NVDX3

Detailed Description

This is a prospective, single arm, single-center PoC study in adult patients, suffering from a degenerative lumbar (L1-S1) spondylolisthesis, treated by spondylodesis in which NVDX3, an osteogenic implant from human allogeneic origin is used. The screening and implant surgery visits will be used as the reference timepoint respectively for the clinical and the radiological efficacy outcome evaluations.

As per standard of care, patients with DLS are followed up to 12 months post-intervention. In the context of this trial, patient safety and IMP efficacy will be followed up to 24 months post-implant surgery.

• Study Type: Interventional
• Enrollment (Actual): 5
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Luxembourg
  • Luxembourg, Luxembourg, 1210
    • Centre Hospitalier de Luxembourg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female patients aged ≥18 years to ≤80 years.

2. Patient diagnosed with symptomatic DLS with confirmed:

   1. Classification: Meyerding grade I or II DLS
   2. One vertebral segment within the lumbar region from L1-S1
   3. Availability of AP and LAT X-ray, MRI and/or CT scan at which the diagnosis was made.
3. The estimated volume of targeted disc space to be filled (both inside and around the interbody cage) should not exceed 10cc.
4. Clinically meaningful pain or neurological symptoms with or without claudication confirmed by a preoperative ODI score >30, which have been unresponsive to a minimum of 3 consecutive months of structured conservative medical management (including at least pain medication, activity modification, and daily exercise).
5. Patient is eligible for surgery by minimally invasive or open transforaminal lumbar interbody fusion (TLIF)3.
6. Patient has understood and accepted to participate in the study according to all study procedures by signing the informed consent.

Exclusion Criteria:

1. History of previously attempted spinal fusion at the same vertebral level, or at a level immediately adjacent to the level intended to undergo the spondylodesis. Decompressive surgery alone (laminectomy) is not an exclusion criterion.
2. Patient with a BMI of ≥35.
3. Presence of clinically significant infection at the target implant site or presence of any systemic infection.

4. History of allergic reaction or any anticipated hypersensitivity to any of the following:

   1. Osteosynthesis materials (eg.cage, screws, rods,…),
   2. Anesthetic agents,
   3. Components of the NVDX3 implant
5. Presence of any auto-immune disease, with exception of well controlled diabetes type-1 or II, or auto-immune thyroid disorders.
6. Positive serology for human immunodeficiency virus (HIV), HBcAb and/or HBsAg.
7. Presence of an active tumor.
8. Documented metabolic bone disease or any disorder, such as but not limited to high-risk osteoporosis, that could interfere with the bone healing and bone metabolism.
9. Documented disease limiting mobility and functional assessments.
10. Chronic, ongoing, or planned use of medications that might affect bone metabolism or bone quality such as bisphosphonates, steroids, methotrexate, anticoagulants, immunosuppressants or immunotherapy.
11. Excessive smoking or history of chronic alcohol or drug abuse within the 12 months prior to screening
12. Use of any investigational drug within 60 days prior to screening.
13. Pregnant women or women of childbearing potential (WOCBP) not agreeing to use effective an effective method of birth control4 during the course of the study. Note: WOCBP including peri-menopausal women who have had a menstrual period within 1 year prior to surgery have to have a negative pregnancy test before entering in the study.
14. Any other psychosocial, mental and physical condition which, in the opinion of the investigator, could interfere with the trial conduct, the patient's compliance or influence interpretation of the results.
15. Patient with historically elevated radiation exposure levels that could in the opinion of the investigator introduce unacceptable radiation risks for the patient, when being accumulated with the radiological examinations planned in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NVDX3 osteogenic implant	Drug: NVDX3; NVDX3 is implanted during a single surgical intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Safety Endpoint	Description of all SAEs and NVDX3 related AEs	Up to 24 months post implant surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety: all acute SAEs and NVDX3 related AEs	Description of all acute SAEs and NVDX3 related AEs	Between screening (V1) and 6 weeks post-IS (V4)
Safety: all SAEs and NVDX3 related AEs	Description of all SAEs and NVDX3 related AEs	Beyond 6 weeks (V4 excluded) until 12 months post-IS
Safety: all SAEs and NVDX3 related AEs	Description of all SAEs and NVDX3 related AEs	Beyond 12 months (V7 excluded) until 24 months post-IS
Safety: TEAEs	Description of Treatment Emergent AEs (TEAEs)	a. Between screening and week 6 (V4 included) b. Between week 6 (V4 excluded) till month 12 (V7 included) c. Between month 12 (V7 excluded) till month 24 (V9 included) d. Full study duration
Safety: related and unexpected (S)AEs	Description of related and unexpected (S)AEs	Between screening (v1) till 24 months post-IS
Safety: AESI	Description of AE of Special Interest (AESI)	Between screening (v1) till 24 months post-IS
Safety: Lab data	Description of lab data	Between screening (v1) till 24 months post-IS
Safety: vital signs: physiological parameters	Description of vital signs: body temperature, pulse rate, respiratory rate and blood pressure	Between screening (v1) till 24 months post-IS
Efficacy: Radiological assessments	Evaluate presence of cortical and trabecular bone formation	a. 4 and 12 months post-IS based on CT compared to Hospital Discharge image acquisition and b. 24-months post-IS based on X-rays compared to the first post-operative X-ray acquisitions taken at 6 weeks post-IS
Efficacy: Radiological assessments	Evaluate presence of spinal fusion (Interbody/disc and facet joint fusion status)	a. 4 and 12 months post-IS based on CT compared to Hospital Discharge image acquisition and b. 24-months post-IS based on X-rays compared to the first post-operative X-ray acquisitions taken at 6 weeks post-IS
Efficacy: Radiological assessments	Measure the average disc height variations based on CT	At Hospital Discharge, 4 and 12 months post-IS
Efficacy: Clinical assessments: investigator questionnaire	Physician rated Clinical Global Impression scale (CGI)	At hospital discharge, 6 weeks, 4-, 6-, 12-, 18- and 24-months post-IS
Efficacy: Clinical assessments: patient questionnaire	Patient reported Functional assessments using the ODI	At hospital discharge, 6 weeks, 4-, 6-, 12-, 18- and 24-months post-IS
Efficacy: Clinical assessments: patient questionnaire	Patient reported Numeric rating scale (NRS) for pain	At hospital discharge, 6 weeks, 4-, 6-, 12-, 18- and 24-months post-IS

Collaborators and Investigators

• Sponsor: Novadip Biosciences
• Collaborators: PrimeVigilance; Data Investigation Company Europe (DICE)
• Investigators: Principal Investigator: David BREUSKIN, MD, Centre Hospitalier du Luxembourg

Study record dates

Study Major Dates

• Study Start (Actual): October 12, 2023
• Primary Completion (Estimated): April 18, 2026
• Study Completion (Estimated): April 18, 2026

Study Registration Dates

• First Submitted: July 11, 2023
• First Submitted That Met QC Criteria: July 18, 2023
• First Posted (Actual): July 27, 2023

Study Record Updates

• Last Update Posted (Actual): December 24, 2025
• Last Update Submitted That Met QC Criteria: December 18, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Spinal Diseases; Bone Diseases; Spondylolysis; Spondylosis; Spondylolisthesis
• Other Study ID Numbers: NVDX3-CLN02; 2022-002771-11 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No